Malignancy Clinical Trial
Official title:
Application of Al18F-NOTA-FAPI PET/CT in Malignant Tumors Expressing Fibroblast-activated Proteins
This is an open-label whole-body PET/CT study for investigating the value of Al18F-NOTA-FAPI PET/CT in patients with malignant tumors expressing fibroblast-activated proteins
Tumour tissue includes tumour cells as well as stromal cells (vascular cells, inflammatory cells, fibroblasts etc.). Activated fibroblasts are present not only in tumours but also in wound healing and diseases with stromal remodelling, such as chronic inflammation, myocardial infarction and liver and lung fibrosis.There is a correlation between FAP expression and tumour microvascular density and FAP expression is strongly associated with poor prognosis in a variety of tumours (e.g. colon, pancreatic, ovarian and hepatocellular carcinoma).Over 90% of FAP-positive cancer-associated fibroblasts are found in epithelial tumours, whereas fibroblasts in normal tissues rarely or even do not express FAP, making FAP a potential target for imaging and treatment of various malignancies. Al18F-NOTA-FAPI is a posionuclide 18F-labelled tumour developer targeting FAP. Current domestic and international studies have shown that it has good stability and high FAP specificity, and shows excellent imaging quality and tumour detection in tumour-bearing mice and cancer patients, and can be used as a broad-spectrum tumour developer for clinical PET/CT imaging for diagnosis and efficacy assessment of tumour patients. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05640115 -
Obstruction of Malignancy: Percutaneous Renal vs Endoscopic Stent
|
Early Phase 1 | |
| Recruiting |
NCT02891642 -
Liquid Biopsy With Immunomagnetic Beads Capture Technique for Malignant Cell Detection in Body Fluid
|
||
| Completed |
NCT02282449 -
Power Injectable Versus a Non-Power Injectable, Upper Arm, TIVAD for Chemotherapy
|
N/A | |
| Completed |
NCT01199822 -
Study of the Safety and Pharmacokinetics of IMC-3G3 in Japanese Patients With Solid Tumors
|
Phase 1 | |
| Completed |
NCT01212731 -
Skull Base and Low Grade Glioma Neurocognitive Magnetic Resonance Imaging (MRI) Study
|
||
| Recruiting |
NCT04122469 -
The Role of Stereo-tActic BoDy RadIotherApy iN Oligo-Progressive MalignanT Disease
|
N/A | |
| Recruiting |
NCT03561727 -
Risk Factors for Development of Incisional Hernia in Transverse Incisions
|
N/A | |
| Terminated |
NCT03251924 -
A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03997968 -
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT00092222 -
Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity
|
Phase 2 | |
| Recruiting |
NCT05770102 -
DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05886764 -
Novel Outreach Methods to Increase Enrollment to Early Phase Clinical Trials
|
N/A | |
| Not yet recruiting |
NCT05992363 -
Tandem Polyurethane Stents Compared to Single Silicone Stent for Malignant Ureteral Obstruction
|
Phase 3 | |
| Recruiting |
NCT05761366 -
Application of 18F-PSMA PET / CT Imaging in Prostate Specific Membrane Antigen Positive Tumor
|
Phase 2 | |
| Recruiting |
NCT04887545 -
Immune- and Microenvironment- Proteogenomics Profiling for Classifying Lung Cancer Patients
|
||
| Completed |
NCT03061955 -
Safety and Efficacy of Concurrent Administration of Influenza Vaccine in Patients Undergoing Anti-PD-1 Immunotherapy (Nivolumab, Pembrolizumab)
|
||
| Completed |
NCT03909464 -
Non-Invasive Neurosensory Testing For Chemotherapy-Induced Peripheral Neuropathy
|
||
| Active, not recruiting |
NCT02649491 -
Using an Electronic Nose to Predict Gastrointestinal Consequences of Pelvic Radiotherapy
|
N/A | |
| Recruiting |
NCT02776995 -
Tumor Monitoring Using Thermography During Radiation Therapy
|
N/A | |
| Active, not recruiting |
NCT01242072 -
Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies
|
Phase 1 |